Dostarlimab (Jemperli)

Canada’s Drug Agency (CDA-AMC) recommends that Jemperli in combination with carboplatin-paclitaxel be reimbursed for the treatment of adults with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy, if certain conditions are met. Jemperli in combination with carboplatin-paclitaxel should only be covered to treat adult patients who have primary stage III or IV endometrial cancer, experienced a first disease recurrence and have not previously received systemic anticancer therapy for advanced disease, received previous systemic anticancer therapies before (neoadjuvant) or after (adjuvant) surgical removal of the tumour and experienced a first recurrence of disease at least 6 months after the completion of adjuvant or neoadjuvant treatment, and are in relatively good health (as measured by performance status). Jemperli should only be reimbursed in combination with carboplatin-paclitaxel if prescribed by clinicians with expertise in advanced endometrial cancer. Treatment should be supervised and administered in institutions with expertise in systemic therapy delivery. The cost of Jemperli should be reduced.